You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma

 

Online download statistics by month:

Online download statistics by month: October 2020 to January 2026

AbstractFullPdf
Oct 2020256257123
Nov 202014014065
Dec 2020626234
Jan 2021858536
Feb 2021535315
Mar 2021454528
Apr 2021383824
May 2021464628
Jun 2021292823
Jul 2021353525
Aug 2021333320
Sep 2021353528
Oct 2021333337
Nov 2021292929
Dec 2021343418
Jan 2022464717
Feb 2022242510
Mar 2022414525
Apr 2022313325
May 2022525537
Jun 2022434834
Jul 2022323211
Aug 2022353625
Sep 2022343423
Oct 2022283123
Nov 202225258
Dec 2022242411
Jan 2023303018
Feb 2023474714
Mar 2023353624
Apr 202319199
May 2023272713
Jun 2023394217
Jul 2023323412
Aug 2023373714
Sep 202324249
Oct 202321229
Nov 2023252517
Dec 2023444413
Jan 2024282911
Feb 2024909020
Mar 2024343475
Apr 2024474935
May 202432325
Jun 2024333512
Jul 2024586016
Aug 202414147
Sep 2024202215
Oct 2024383824
Nov 2024262816
Dec 2024353516
Jan 2025383814
Feb 2025394022
Mar 2025434432
Apr 2025596013
May 2025464725
Jun 2025202217
Jan 2026110
Total244924931326